Publicaciones en colaboración con investigadores/as de University of Manchester (9)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

  2. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075

2022

  1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

2021

  1. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

  2. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

    Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184

2020

  1. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

  2. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166